22.39
1.80%
+0.395
Silence Therapeutics Plc ADR stock is currently priced at $22.39, with a 24-hour trading volume of 7,169.
It has seen a +1.80% increased in the last 24 hours and a +5.84% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $21.87 pivot point. If it approaches the $22.68 resistance level, significant changes may occur.
Previous Close:
$21.99
Open:
$22.09
24h Volume:
7,169
Market Cap:
$1.03B
Revenue:
$31.37M
Net Income/Loss:
$-53.77M
P/E Ratio:
-15.73
EPS:
-1.4232
Net Cash Flow:
$-49.02M
1W Performance:
+2.31%
1M Performance:
+5.84%
6M Performance:
+121.85%
1Y Performance:
+0.00%
Silence Therapeutics Plc ADR Stock (SLN) Company Profile
Name
Silence Therapeutics Plc ADR
Sector
Industry
Phone
44 20 3457 6900
Address
72 Hammersmith Road, London
Silence Therapeutics Plc ADR Stock (SLN) Latest News
Beyond The Numbers: 7 Analysts Discuss Silence Therapeutics Stock
Benzinga
Silence Therapeutics (SLN) Surges 5.7%: Is This an Indication of Further Gains?
Zacks Investment Research
These Analysts Boost Their Forecasts On Silence Therapeutics After Full Year 2023 Results
Benzinga
What 4 Analyst Ratings Have To Say About Silence Therapeutics
Benzinga
MediWound (MDWD) Moves 7.1% Higher: Will This Strength Last?
Zacks Investment Research
Silence Therapeutics PLC Sponsored ADR (SLN) Soars 6.4%: Is Further Upside Left in the Stock?
Zacks Investment Research
Silence Therapeutics Plc ADR Stock (SLN) Financials Data
Silence Therapeutics Plc ADR (SLN) Revenue 2024
SLN reported a revenue (TTM) of $31.37 million for the quarter ending December 31, 2023, a +43.72% rise year-over-year.
Silence Therapeutics Plc ADR (SLN) Net Income 2024
SLN net income (TTM) was -$53.77 million for the quarter ending December 31, 2023, a -7.83% decrease year-over-year.
Silence Therapeutics Plc ADR (SLN) Cash Flow 2024
SLN recorded a free cash flow (TTM) of -$49.02 million for the quarter ending December 31, 2023, a +13.75% increase year-over-year.
Silence Therapeutics Plc ADR (SLN) Earnings per Share 2024
SLN earnings per share (TTM) was -$1.4537 for the quarter ending December 31, 2023, a +7.06% growth year-over-year.
About Silence Therapeutics Plc ADR
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's mRNAi GOLD GalNAc Oligonucleotide Discovery platform that is used to target specific disease-associated genes in the liver. Its siRNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company develops SLN360, which is in phase 2 clinical development to reduce high levels of lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase I clinical trials for the treatment of myelodysplastic syndrome; and polycythemia vera. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize small interfering siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three undisclosed targets leveraging Silence's mRNAi GOLD platform, as well as the company also collab with Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.
Cap:
|
Volume (24h):